These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 12678778)

  • 1. Anticancer drug discovery using chemical genomics.
    Sehgal A
    Curr Med Chem; 2003 May; 10(9):749-55. PubMed ID: 12678778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yeast genomics and proteomics in drug discovery and target validation.
    Parsons AB; Geyer R; Hughes TR; Boone C
    Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of emerging genomics and proteomics technologies in cancer drug target discovery.
    Onyango P
    Curr Cancer Drug Targets; 2004 Mar; 4(2):111-24. PubMed ID: 15032664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical genomics strategy for the discovery of new anticancer agents.
    Jung M; Kim H; Kim M
    Curr Med Chem; 2003 May; 10(9):757-62. PubMed ID: 12678779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of individual response to anticancer therapy: historical and future perspectives.
    Unger FT; Witte I; David KA
    Cell Mol Life Sci; 2015 Feb; 72(4):729-57. PubMed ID: 25387856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.
    Smith SC; Baras AS; Lee JK; Theodorescu D
    Cancer Res; 2010 Mar; 70(5):1753-8. PubMed ID: 20160033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
    Ferrer-Alcón M; Arteta D; Guerrero MJ; Fernandez-Orth D; Simón L; Martinez A
    Toxicol Lett; 2009 Apr; 186(1):45-51. PubMed ID: 19022361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalised medicine for cancer: from drug development into clinical practice.
    Jain KK
    Expert Opin Pharmacother; 2005 Aug; 6(9):1463-76. PubMed ID: 16086635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug discovery and development using chemical genomics.
    Sehgal A
    Curr Opin Drug Discov Devel; 2002 Jul; 5(4):526-31. PubMed ID: 12197310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomics and proteomics tools for compound mode-of-action studies in drug discovery.
    Kley N; Ivanov I; Meier-Ewert S
    Pharmacogenomics; 2004 Jun; 5(4):395-404. PubMed ID: 15165175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Target validation and drug discovery using genomic and protein-protein interaction technologies.
    Pillutla RC; Fisher PB; Blume AJ; Goldstein NI
    Expert Opin Ther Targets; 2002 Aug; 6(4):517-31. PubMed ID: 12223066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer drug development at the US National Cancer Institute.
    Takimoto CH
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S29-33. PubMed ID: 12819935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contemporary drug development process: advances and challenges in preclinical and clinical development.
    Garrett MD; Walton MI; McDonald E; Judson I; Workman P
    Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the outcomes: developing cancer therapeutics.
    Utku N
    Future Oncol; 2012 Jan; 8(1):87-103. PubMed ID: 22149037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.
    Geromichalos GD; Alifieris CE; Geromichalou EG; Trafalis DT
    J BUON; 2016; 21(4):764-779. PubMed ID: 27685895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.